Huntington’s Disease Treatment Market Research Report - Forecast till 2027

Huntington's Disease Treatment Market Research Report: by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), Treatment (symptomatic therapy, disease-modifying therapy), End-users (hospital and others) - Forecast Till 2027

ID: MRFR/Pharma/5466-HCR | February 2021 | Region: Global | 90 pages

Huntington's Disease Treatment Market Scenario:


Huntington’s Disease Treatment Market is expected to rise steadily at a CAGR of 40% during forecast period of 2018-2023.


Huntington’s Disease is a genetic disorder that causes degeneration of nerve cells in brain. The degeneration of brain cells controls movement, intellectual ability and behaviour of that person. This disease normally appears at the age of 30-50 and gets worsen within 10-25 years of time. Huntington’s disease is fatal and there is no cure for this disease.


The Huntington’s Disease Treatment Market is largely driven by factors such as increased adoption of novel therapeutics, increase in R&D activities, rise in target population and favourable government initiatives. The huntington’s disease pipeline will see the new development in coming years as the disease modifying drugs transforms the market landscape. Many key players in market are engaged in development of new drug products for the treatment of huntington disease. At present, more than 20 products are being studied for treatment for huntington’s disease in various stages of clinical trials.


However certain factors that can hamper the growth of this market in near future are lack of awareness regarding genetic disorders and alternative treatment plans. 


Segmentation:


Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users. On basis of drug type the Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Huntington’s Disease Treatment Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injury market.  The European Huntington’s Disease Treatment Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The Huntington’s Disease Treatment Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The huntington’s disease treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


Some of the key players in the Huntington’s Disease Treatment Market are Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc.


Regional Market Summary


Global Huntington’s Disease Treatment Market Share (%), by Region, 2017


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon


Geographically, the America holds the highest market share for huntington’s disease treatment market and the reason being many market players are engaged in development of new drug product innovation. According to the survey carried out by one of the University of Sheffield, the estimated prevalence of huntington’s disease in North America, North Western Europe and Australia ranges from 5.96 to 13.7 cases per 100 000 population.


Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of targeted population, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. 


The prevalence of huntington’s disease is significantly lower in Asian populations compared to Western Europe, North America and Australia.


The market in the Middle East & Africa is likely to account for the smallest share of the global huntington’s disease treatment.


Huntington’s Disease Treatment Market by Drug Type:



  •      Tetrabenazine

  •      Deutetrabenazine

  •      Selective Serotonin Reuptake Inhibitor (SSRI)

  •      Chlorpromazine

  •      Haloperidol

  •      Risperidone

  •      Olanzapine

  •      Clozapine

  •      Other


Huntington’s Disease Treatment Market, by Treatment:



  •      Symptomatic Therapy

  •      Disease-Modifying Therapy


Huntington’s Disease Treatment Market, by End-Users:



  •       Hospital

  •       Clinics

  •       Online Pharmacies

  •       Retail Pharmacies

  •       Others


Huntington’s Disease Treatment Market, by Region:



  • Americas

    •  North America

      •     US

      •     Canada



    •  South America



  • Europe

    •  Western Europe

      •   Germany

      •     France

      •   Italy

      •   Spain

      •   UK

      •   Rest of Western Europe



    •  Eastern Europe



  • Asia Pacific

    •   Japan

    •   China

    •  India

    • Australia  

    • Republic of Korea 

    • Rest of Asia Pacific 



  • The Middle East & Africa

    •   Middle East

    •   Africa




Huntington’s Disease Treatment Market Key Players:



  •        Alnylam Pharmaceuticals Inc

  •        AmpliPhi Biosciences Corp

  •        Ceregene Inc

  •        Lundbeck

  •        Prana Biotechnology Limited

  •        Teva Pharmaceutical Industries Ltd

  •        Cortex Pharmaceuticals Inc

  •        Vertex Pharmaceuticals Incorporated

  •        Auspex Pharmaceuticals

  •        SOM Biotech

  •        GlaxoSmithKline

  •        Siena Biotech

  •        Raptor Pharmaceutical

  •        Pfizer

  •        Palobiofarma

  •        Omeros

  •        Ipsen

  •        Valeant Pharmaceuticals International Inc


Intended Audience:



  • Manufacturers and Suppliers

  • Hospitals and Clinics

  • Laboratories and Associations

  • Research and Development (R&D) Companies

  • Government research institutes

  • Academic institutes and universities



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   40% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug type, Treatment and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increased adoption of novel therapeutics
  • Increase in R&D activities
  • Rise in target population and favourable government initiatives


  • Speak to Analyst Ask for Customization

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Huntington’s Disease Treatment Market, by Drug Type

    6.1 Introduction

    6.2 Tetrabenazine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Deutetrabenazine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Selective Serotonin Reuptake Inhibitor (SSRI)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.5 Chlorpromazine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.6 Haloperidol

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.7 Risperidone

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.8 Olanzapine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.9 Clozapine

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.10 Other

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Huntington’s Disease Treatment Market, by Treatment

    7.1 Introduction

    7.2 Symptomatic therapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Disease-Modifying therapy

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8. Global Huntington’s Disease Treatment Market, by End-Users

    8.1 Introduction

    8.2 Hospital

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Retail Pharmacies

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5 Online Pharmacies

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.6 Others

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 9. Global Huntington’s Disease Treatment Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 South Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 Middle East

    9.5.2 Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    Chapter 11. Company Profiles

    11.1 Pfizer, Inc.

    11.1.1 Company Overview

    11.1.2 Product Overview

    11.1.3 Financials Overview

    11.1.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Alnylam Pharmaceuticals Inc

    11.2.1 Company Overview

    11.2.2 Product Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 AmpliPhi Biosciences Corp

    11.3.1 Company Overview

    11.3.2 Product Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Ceregene Inc

    11.4.1 Company Overview

    11.4.2 Product Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Prana Biotechnology Limited

    11.5.1 Company Overview

    11.5.2 Product Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Teva Pharmaceutical Industries Ltd

    11.6.1 Company Overview

    11.6.2 Product Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Cortex Pharmaceuticals Inc

    11.7.1 Overview

    11.7.2 Product Overview

    11.7.3 Financial Overview

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Vertex Pharmaceuticals Incorporated

    11.8.1 Overview

    11.8.2 Product Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Auspex Pharmaceuticals

    11.9.1 Overview

    11.9.2 Product Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 SOM Biotech

    11.10.1 Overview

    11.10.2 Product Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 GlaxoSmithKline

    11.11.1 Overview

    11.11.2 Product Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Siena Biotech

    11.12.1 Overview

    11.12.2 Product Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Raptor Pharmaceutical

    11.13.1 Overview

    11.13.2 Product Overview

    11.13.3 Financials

    11.13.4 Key Developments

    11.13.5 SWOT Analysis

    11.14 Palobiofarma

    11.14.1 Overview

    11.14.2 Product Overview

    11.14.3 Financials

    11.14.4 Key Developments

    11.14.5 SWOT Analysis

    11.15 Omeros

    11.15.1Overview

    11.15.2 Product Overview

    11.15.3 Financials

    11.15.4 Key Developments

    11.15.5 SWOT Analysis

    11.16 Ipsen

    11.16.1 Overview

    11.16.2 Product Overview

    11.16.3 Financials

    11.16.4 Key Developments

    11.16.5 SWOT Analysis

    11.17 Valeant Pharmaceuticals International Inc

    11.17.1 Overview

    11.17.2 Product Overview

    11.17.3 Financials

    11.17.4 Key Developments

    11.17.5 SWOT Analysis

    Chapter 12 MRFR Conclusion

    12.1 Key Findings

    12.1.1 From CEO’s Viewpoint

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Predictions for the Global Huntington’s Disease Treatment Market

    Chapter 13. Appendix


    LIST OF TABLES

    Table 1 Global Huntington’s Disease Treatment Market Synopsis, 2020-2027

    Table 2 Global Huntington’s Disease Treatment Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 4 Global Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 5 Global Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 6 Global Huntington’s Disease Treatment Market, by Region, 2020-2027(USD Million)

    Table 7 North America: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 8 North America: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 9 North America: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 10 North America: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 11 US: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 12 US: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 13 US: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 14 US: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 15 Canada: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 16 Canada: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 17 Canada: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 18 Canada: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 19 South America: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 20 South America: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 21 South America: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 22 South America: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 23 Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 24 Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 25 Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 26 Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 27 Western Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 28 Western Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 29 Western Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 30 Western Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 31 Eastern Europe: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 32 Eastern Europe: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 33 Eastern Europe: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 34 Eastern Europe: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 35 Asia-Pacific: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 36 Asia-Pacific: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 37 Asia-Pacific: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 38 Asia-Pacific: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)

    Table 39 Middle East & Africa: Huntington’s Disease Treatment Market, by Drug Type, 2020-2027 (USD Million)

    Table 40 Middle East & Africa: Huntington’s Disease Treatment Market, by Treatment, 2020-2027 (USD Million)

    Table 41 Middle East & Africa: Huntington’s Disease Treatment Market, by End-Users, 2020-2027 (USD Million)

    Table 42 Middle East & Africa: Huntington’s Disease Treatment Market, by Region, 2020-2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Huntington’s Disease Treatment Market

    Figure 3 Segmentation Market Dynamics for Global Huntington’s Disease Treatment Market

    Figure 4 Global Huntington’s Disease Treatment Market Share, by Drug Type, 2020(%)

    Figure 5 Global Huntington’s Disease Treatment Market Share, by Treatment, 2020(%)

    Figure 6 Global Huntington’s Disease Treatment Market Share, by End-Users, 2020(%)

    Figure 7 Global Huntington’s Disease Treatment Market Share, by Region, 2020(%)

    Figure 8 North America: Huntington’s Disease Treatment Market Share, by Country, 2020(%)

    Figure 9 Europe: Huntington’s Disease Treatment Market Share, by Country, 2020(%)

    Figure 10 Asia-Pacific: Huntington’s Disease Treatment Market Share, by Country, 2020(%)

    Figure 11Middle East & Africa: Huntington’s Disease Treatment Market Share, by Country,2020(%)

    Figure 12 Global Huntington’s Disease Treatment Market: Company Share Analysis, 2020(%)

    Figure 13 Pfizer, Inc: Key Financials

    Figure 14 Pfizer, Inc: Segmental Revenue

    Figure 15 Pfizer, Inc: Geographical Revenue

    Figure 16 Alnylam Pharmaceuticals Inc: Key Financials

    Figure 17 Alnylam Pharmaceuticals Inc: Segmental Revenue

    Figure 18 Alnylam Pharmaceuticals Inc: Geographical Revenue

    Figure 19 AmpliPhi Biosciences Corp: Key Financials

    Figure 20 AmpliPhi Biosciences Corp: Segmental Revenue

    Figure 21 AmpliPhi Biosciences Corp: Geographical Revenue

    Figure 22 Ceregene Inc: Key Financials

    Figure 23 Ceregene Inc: Segmental Revenue

    Figure 24 Ceregene Inc: Geographical Revenue

    Figure 25 Prana Biotechnology Limited.: Key Financials

    Figure 26 Prana Biotechnology Limited.: Segmental Revenue

    Figure 27 Prana Biotechnology Limited.: Geographical Revenue

    Figure 28 Teva Pharmaceutical Industries Ltd.: Key Financials

    Figure 29 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 30 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

    Figure 31 Cortex Pharmaceuticals Inc: Key Financials

    Figure 32 Cortex Pharmaceuticals Inc: Segmental Revenue

    Figure 33 Cortex Pharmaceuticals Inc: Geographical Revenue

    Figure 34 Vertex Pharmaceuticals Incorporated: Key Financials

    Figure 35 Vertex Pharmaceuticals Incorporated: Segmental Revenue

    Figure 36 Vertex Pharmaceuticals Incorporated: Geographical Revenue

    Figure 37 Auspex Pharmaceuticals: Key Financials

    Figure 38 Auspex Pharmaceuticals: Segmental Revenue

    Figure 39 Auspex Pharmaceuticals: Geographical Revenue

    Figure 40 SOM Biotech: Key Financials

    Figure 41 SOM Biotech: Segmental Revenue

    Figure 42 SOM Biotech: Geographical Revenue

    Figure 43 GlaxoSmithKline: Key Financials

    Figure 44 GlaxoSmithKline: Segmental Revenue

    Figure 45 GlaxoSmithKline: Geographical Revenue

    Figure 46 Siena Biotech: Key Financials

    Figure 47 Siena Biotech: Segmental Revenue

    Figure 48 Siena Biotech: Geographical Revenue

    Figure 49 Raptor Pharmaceutical.: Key Financials

    Figure 50 Raptor Pharmaceutical.: Segmental Revenue

    Figure 51 Raptor Pharmaceutical.: Geographical Revenue

    Figure 52 Palobiofarma: Key Financials

    Figure 53 Palobiofarma: Segmental Revenue

    Figure 54 Palobiofarma: Geographical Revenue

    Figure 55 Omeros: Key Financials

    Figure 56 Omeros: Segmental Revenue

    Figure 57 Omeros: Geographical Revenue

    Figure 58 Ipsen: Key Financials

    Figure 59 Ipsen: Segmental Revenue

    Figure 60 Ipsen: Geographical Revenue

    Figure 61 Valeant Pharmaceuticals International Inc: Key Financials

    Figure 62 Valeant Pharmaceuticals International Inc: Segmental Revenue

    Figure 63 Valeant Pharmaceuticals International Inc: Geographical Revenue